Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.
Gianluigi SavareseC HageL BensonB SchrageT ThorvaldsenA LundbergM FudimC LindeU DahlströmG M C RosanoL H LundPublished in: Journal of internal medicine (2020)
In a real-world HF outpatient cohort, 81% of patients had EF < 50%, with 63% eligible for sacubitril/valsartan based on pragmatic criteria and 32% eligible based on literal trial criteria. Similar eligibility was observed for EF 40-49% and ≥50%, suggesting that our estimates for EF < 50% may be reproduced whether or not a higher cut-off for EF is considered.
Keyphrases
- ejection fraction
- heart failure
- aortic stenosis
- study protocol
- acute heart failure
- left ventricular
- atrial fibrillation
- end stage renal disease
- phase iii
- cardiac resynchronization therapy
- electronic health record
- newly diagnosed
- randomized controlled trial
- coronary artery disease
- big data
- phase ii
- machine learning
- peritoneal dialysis
- open label
- prognostic factors
- aortic valve